{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T18:33:41Z","timestamp":1786473221817,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semarthrit.2025.152789","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T15:30:01Z","timestamp":1752852601000},"page":"152789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Current evidence on switching between biologic therapies for Still\u2019s disease: A systematic literature review"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Schuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152789_bib0001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","article-title":"Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity","volume":"13","author":"Nirmala","year":"2015","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0002","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease","author":"Fautrel","year":"2024831614","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset Still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0004","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3389\/fphar.2016.00467","article-title":"IL-1 inhibition in systemic juvenile idiopathic arthritis","volume":"7","author":"Giancane","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0005","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1136\/ard-2024-225853","article-title":"Systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease","volume":"83","author":"De Matteis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152264","article-title":"Burden of adult-onset Still's disease: a systematic review of health-related quality of life, utilities, costs and resource use","volume":"63","author":"Ruscitti","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0007","first-page":"920","article-title":"The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review","volume":"36","author":"Shenoi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00393-022-01294-2","article-title":"Diagnosis and treatment of adult-onset Still's disease: a concise summary of the German society of rheumatology S2 guideline","volume":"82","author":"Vordenbaumen","year":"2023","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-024-01993-x","article-title":"Adult-Onset still's disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options","volume":"84","author":"Bindoli","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0010","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040733","article-title":"Adult-Onset Still's disease: clinical aspects and therapeutic approach","volume":"10","author":"Tomaras","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101632","article-title":"The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients","volume":"58","author":"Ruscitti","year":"2021","journal-title":"Semin Immunol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0013","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cyto.2012.11.025","article-title":"Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles","volume":"61","author":"Shimizu","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0014","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semarthrit.2017.11.002","article-title":"Growth patterns in early juvenile idiopathic arthritis: results from the childhood arthritis prospective Study (CAPS)","volume":"48","author":"McErlane","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OARRR.S151013","article-title":"Macrophage activation syndrome: early diagnosis is key","volume":"10","author":"Lerkvaleekul","year":"2018","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103400","article-title":"Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission","volume":"22","author":"Giacomelli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","article-title":"Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany","volume":"16","author":"Hinze","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0018","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0019","first-page":"33","article-title":"Treatment of adult-onset Still's disease: a review","volume":"11","author":"Jamilloux","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-019-2021-9","article-title":"Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts","volume":"21","author":"Colafrancesco","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"suppl 9","key":"10.1016\/j.semarthrit.2025.152789_bib0021","article-title":"EULAR \/PreS recommendations for the diagnosis andManagement of systemic juvenile idiopathic arthritis (sJIA) and adult onset Still\u2019s disease (AOSD). Presented at the American College of Rheumatology Convergence 2023. Abstract number 0761","volume":"75","author":"Fautrel","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0022","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.41612","article-title":"Early treatment and IL1RN single-nucleotide polymorphisms affect response to Anakinra in systemic juvenile idiopathic arthritis","volume":"73","author":"Pardeo","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0023","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13075-017-1462-2","article-title":"Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry","volume":"19","author":"Horneff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0024","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00296-016-3595-z","article-title":"Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis","volume":"37","author":"Pacharapakornpong","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0025","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/ard-2024-225854","article-title":"Efficacy and safety of therapies for Still\u2019s disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR\/PReS guidelines for the management of Still\u2019s disease","volume":"83","author":"Bindoli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0026","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0028","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/cei\/uxad045","article-title":"The clinical and experimental treatment of juvenile idiopathic arthritis","volume":"213","author":"Nijhuis","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0029","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead461","article-title":"Management of adult-onset Still\u2019s disease: evidence- and consensus-based recommendations by experts","author":"Leavis","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0031","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/acr.24853","article-title":"2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0032","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.autrev.2017.07.017","article-title":"How I treat patients with adult onset Still's disease in clinical practice","volume":"16","author":"Govoni","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0033","article-title":"Care pathway analysis and evidence gaps in adult-onset Still's disease: interviews with experts from the UK, France, Italy, and Germany","volume":"10","author":"Ursini","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0034","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpam.2021.05.003","article-title":"Consensus clinical approach for a newly diagnosed systemic juvenile idiopathic arthritis among members of the pediatric rheumatology Arab group","volume":"8","author":"Alkwai","year":"2021","journal-title":"Int J Pediatr Adolesc Med"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0035","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/14397595.2018.1465633","article-title":"Evidence-based clinical practice guideline for adult Still's disease","volume":"28","author":"Mimura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0036","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0037","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/mr\/roac128","article-title":"Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: results from an open-label Phase III study","volume":"33","author":"Iwata","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0038","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2020-217155","article-title":"Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial","volume":"79","author":"Kedor","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0039","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12969-019-0364-z","article-title":"Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial","volume":"17","author":"Mallalieu","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0040","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/14397595.2020.1783163","article-title":"Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients","volume":"31","author":"Nishimura","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0041","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/art.41488","article-title":"Tapering Canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from a phase IIIb\/IV open-label, randomized study","volume":"73","author":"Quartier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0042","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0043","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still's disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-017-0157-1","article-title":"Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic juvenile idiopathic arthritis consensus treatment plans","volume":"15","author":"Kimura","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1114207","article-title":"Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: a single-centre cohort study using routinely collected health data","volume":"11","author":"Alexeeva","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000036","article-title":"Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent","volume":"1","author":"Woerner","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0047","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/1756-185X.13649","article-title":"Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: a single-center experience","volume":"22","author":"Barut","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0048","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8054961","article-title":"Real-life data on the efficacy of Canakinumab in patients with adult-onset still's disease","volume":"2020","author":"Vitale","year":"2020","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0049","first-page":"1598","article-title":"Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease","volume":"40","author":"Campochiaro","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2020.10.011","article-title":"Outcome of refractory to conventional and\/or biologic treatment adult Still's disease following canakinumab treatment: countrywide data in 50 patients","volume":"51","author":"Laskari","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0051","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/art.41436","article-title":"Efficacy and safety of Canakinumab in patients with systemic juvenile idiopathic arthritis with and without fever at baseline: results from an open-label, active-treatment extension study","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0052","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/rheumatology\/keab619","article-title":"Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort","volume":"61","author":"De Matteis","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0053","first-page":"194","article-title":"Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study","volume":"42","author":"Sozeri","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0054","doi-asserted-by":"crossref","first-page":"852","DOI":"10.24953\/turkjped.2019.06.005","article-title":"Systemic onset juvenile idiopathic arthritis: a single center experience","volume":"61","author":"Sa\u011f","year":"2019","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-021-00510-8","article-title":"Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry","volume":"19","author":"Lainka","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0056","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40744-021-00402-z","article-title":"Reasons for initiating Canakinumab among patients with systemic juvenile idiopathic arthritis and adult-onset Still's disease in the U.S. Real-World Settings","volume":"9","author":"Hur","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0057","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3899\/jrheum.130881","article-title":"Tocilizumab in adult-onset Still's disease: the Israeli experience","volume":"41","author":"Elkayam","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0058","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0059","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12969-018-0236-y","article-title":"IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry)","volume":"16","author":"Bielak","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0060","first-page":"S64","article-title":"Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases","volume":"34","author":"Song","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0061","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MD.0000000000000021","article-title":"Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients","volume":"93","author":"Gerfaud-Valentin","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0062","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of Anakinra in refractory adult-onset Still's disease: multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanju\u00e1n","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0063","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: a multicentre retrospective observational study","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0064","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fphar.2019.00296","article-title":"Long-term retention rate of Anakinra in adult onset still's disease and predictive factors for treatment response","volume":"10","author":"Vitale","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey","volume":"10","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0066","article-title":"Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's Disease","volume":"10","author":"Vitale","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0067","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keac440","article-title":"JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis","volume":"62","author":"Gillard","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1134312","article-title":"JAK inhibitors in systemic juvenile idiopathic arthritis","volume":"11","author":"He","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0069","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12969-024-00974-4","article-title":"Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience","volume":"22","author":"Qiu","year":"2024","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1349907","article-title":"Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China","volume":"12","author":"Zhu","year":"2024","journal-title":"Front Pediatr"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0071","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12969-022-00768-6","article-title":"First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans","volume":"20","author":"Beukelman","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0072","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fmed.2020.00042","article-title":"Comparison of early vs. delayed Anakinra treatment in patients with adult onset Still's disease and effect on clinical and laboratory outcomes","volume":"7","author":"Vitale","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.semarthrit.2025.152789_bib0073","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.42137","article-title":"The conundrum of lung disease and drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis","volume":"74","author":"Binstadt","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722500160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722500160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:58:36Z","timestamp":1780120716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722500160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":73,"alternative-id":["S004901722500160X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152789","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current evidence on switching between biologic therapies for Still\u2019s disease: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152789"}}